The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

JPMorgan Chase & Co. grew its position in shares of Bioceres Crop Solutions Corp. (NASDAQ:BIOX – Free Report) by 49.3% in the ...

The proposed funds, which include the VanEck Solana Trust, 21Shares Core Solana ETF, Canary Solana ETF, and Bitwise Solana ...

Shares of Upstream Bio, Inc. (NASDAQ:UPB – Get Free Report) fell 3.9% on Friday . The company traded as low as $10.46 and last traded at $10.36. 8,771 shares changed hands during mid-day trading, a ...

The House Oversight Committee is asking "tech leaders who have spoken publicly about debanking to share their stories." ...

Kevin Willsey, a JPMorgan Chase & Co. global chair of investment banking and capital markets, is retiring after more than ...

Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for ...

Some of the other senior executives at the bank also saw their compensation rising by between 4% and 21% in 2024.

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

RBC Wealth Management continues to recruit top advisory talent away from large Wall Street firms.

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...